Compared to the control group, the number of CD45+CD3e−MHCII+CD11c+ DCs in the tumor-draining lymph nodes was increased in all treatment groups except the α-PD-1 + α-CTLA-4 and chemo groups; and the difference was statistically significant in the STING/α-PD-1 + α-CTLA-4, NLRP3/α-PD-1 + α-CTLA-4, and chemo > NLRP3/α-PD-1 + α-CTLA-4 groups, but not in the chemo > STING/α-PD-1 + α-CTLA-4 group (Fig. 4A). The gene discussed is PTPRC; the disease is neoplasm.